Recommendations for clinical trial development in follicular lymphoma

Kami Maddocks, Paul M. Barr, Bruce D. Cheson, Richard F. Little, Lawrence Baizer, Brad S. Kahl, John P. Leonard, Nathan Fowler, Leo I. Gordon, Brian K. Link, Jonathan W. Friedberg, Stephen M. Ansell

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

Original languageEnglish
JournalJournal of the National Cancer Institute
Issue number3
StatePublished - Mar 2017


Dive into the research topics of 'Recommendations for clinical trial development in follicular lymphoma'. Together they form a unique fingerprint.

Cite this